INBIOGEN has been growing earnings at an average annual rate of 19.6%, while the Luxury industry saw earnings declining at 1.7% annually. Revenues have been declining at an average rate of 13.4% per year.
How INBIOGEN makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSE:A101140 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
5,444
-18,128
3,280
0
31 Dec 25
6,297
-1,419
3,682
0
30 Sep 25
7,804
26,151
4,602
22
30 Jun 25
7,737
15,029
4,923
22
31 Mar 25
7,312
9,562
5,642
-6
31 Dec 24
7,041
16,122
5,686
0
30 Sep 24
6,436
-6,549
4,975
7
30 Jun 24
5,483
-1,271
5,272
7
31 Mar 24
5,717
5,930
5,261
14
31 Dec 23
6,241
11,859
5,739
8
30 Sep 23
6,174
37,337
6,371
2
30 Jun 23
7,594
29,465
6,639
2
31 Mar 23
9,394
-54,419
6,869
3
31 Dec 22
10,420
-116,949
6,521
4
30 Sep 22
12,796
-17,540
7,925
6
30 Jun 22
12,585
-25,663
8,129
23
31 Mar 22
11,698
4,306
8,321
26
31 Dec 21
10,481
94,125
8,700
25
30 Sep 21
9,029
-55,106
7,531
22
30 Jun 21
9,965
-45,421
6,887
5
31 Mar 21
10,518
-2,190
6,044
0
31 Dec 20
10,218
-45,078
5,492
0
30 Sep 20
10,384
-20,751
4,264
0
30 Jun 20
11,256
103
3,830
0
31 Mar 20
10,521
12,217
3,285
0
31 Dec 19
9,795
13,124
2,393
0
30 Sep 19
8,873
19,966
1,743
0
30 Jun 19
6,753
7,368
-446
0
31 Mar 19
6,345
1,536
-663
0
31 Dec 18
7,566
1,664
-790
0
30 Sep 18
6,836
2,060
-258
0
30 Jun 18
6,665
-827
1,381
0
31 Mar 18
5,999
-1,132
1,744
0
31 Dec 17
7,077
-1,211
1,883
0
30 Sep 17
8,347
-1,518
2,477
0
30 Jun 17
8,134
-1,917
2,578
0
31 Mar 17
9,678
-2,037
2,649
0
31 Dec 16
11,545
-2,256
3,207
0
30 Sep 16
11,970
-2,368
2,398
0
30 Jun 16
11,436
-5,554
5,092
0
31 Mar 16
10,064
-5,617
4,760
0
31 Dec 15
8,865
-5,686
4,540
0
30 Sep 15
8,862
-5,003
4,750
21
30 Jun 15
10,955
-4,357
5,078
1
Quality Earnings: A101140 is currently unprofitable.
Growing Profit Margin: A101140 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A101140 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare A101140's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A101140 is unprofitable, making it difficult to compare its past year earnings growth to the Luxury industry (19.2%).
Return on Equity
High ROE: A101140 has a negative Return on Equity (-12.68%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/28 00:48
End of Day Share Price
2026/06/26 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
INBIOGEN Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.